BR112017017089A2 - complexos de acetato de abiraterona, processo para preparação destes e composições farmacêuticas contendo-os - Google Patents
complexos de acetato de abiraterona, processo para preparação destes e composições farmacêuticas contendo-osInfo
- Publication number
- BR112017017089A2 BR112017017089A2 BR112017017089-2A BR112017017089A BR112017017089A2 BR 112017017089 A2 BR112017017089 A2 BR 112017017089A2 BR 112017017089 A BR112017017089 A BR 112017017089A BR 112017017089 A2 BR112017017089 A2 BR 112017017089A2
- Authority
- BR
- Brazil
- Prior art keywords
- processes
- preparation
- pharmaceutical compositions
- compositions containing
- abiraterone acetate
- Prior art date
Links
- UVIQSJCZCSLXRZ-UBUQANBQSA-N abiraterone acetate Chemical class C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CC[C@@H](CC4=CC[C@H]31)OC(=O)C)C=C2C1=CC=CN=C1 UVIQSJCZCSLXRZ-UBUQANBQSA-N 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Nanotechnology (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Optics & Photonics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HU1500055A HUP1500055A1 (hu) | 2015-02-09 | 2015-02-09 | Abirateron acetát komplexei, eljárás elõállításukra, és az azokat tartalmazó gyógyászati készítmények |
HUP1500055 | 2015-02-09 | ||
PCT/IB2016/050672 WO2016128891A1 (en) | 2015-02-09 | 2016-02-09 | Complexes of abiraterone acetate, process for the preparation thereof and pharmaceutical compositions containing them |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112017017089A2 true BR112017017089A2 (pt) | 2018-06-26 |
Family
ID=89991732
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112017017089-2A BR112017017089A2 (pt) | 2015-02-09 | 2016-02-09 | complexos de acetato de abiraterona, processo para preparação destes e composições farmacêuticas contendo-os |
Country Status (18)
Country | Link |
---|---|
US (4) | US9623034B2 (pt) |
EP (1) | EP3256108B1 (pt) |
JP (1) | JP6697473B2 (pt) |
CN (1) | CN107278152A (pt) |
AR (1) | AR103653A1 (pt) |
AU (1) | AU2016217534A1 (pt) |
BR (1) | BR112017017089A2 (pt) |
CA (1) | CA2976053A1 (pt) |
ES (1) | ES2737955T3 (pt) |
HK (1) | HK1246189B (pt) |
HU (2) | HUP1500055A1 (pt) |
IL (1) | IL253793B (pt) |
MX (1) | MX2017010280A (pt) |
PL (1) | PL3256108T3 (pt) |
RU (1) | RU2017129740A (pt) |
SG (1) | SG11201706273QA (pt) |
TW (1) | TWI696463B (pt) |
WO (1) | WO2016128891A1 (pt) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUP1500055A1 (hu) | 2015-02-09 | 2016-08-29 | Druggability Technologies Ip Holdco Ltd | Abirateron acetát komplexei, eljárás elõállításukra, és az azokat tartalmazó gyógyászati készítmények |
EP3280448B1 (en) | 2015-04-10 | 2020-12-30 | Capsugel Belgium NV | Abiraterone acetate lipid formulations |
WO2018111991A1 (en) * | 2016-12-14 | 2018-06-21 | Druggability Technologies Ip Holdco Limited | Pharmaceutical composition containing celecoxib |
JP2020502144A (ja) * | 2016-12-19 | 2020-01-23 | ドラッガビリティー テクノロジーズ アイピー ホールディング カンパニー リミテッドDruggability Technologies Ip Holdco Limited | スボレキサントの医薬製剤 |
AU2018316248A1 (en) * | 2017-08-09 | 2020-01-30 | Nangenex Nanotechnology Incorporated | Pharmaceutical composition comprising Abiraterone acetate and Darulotamide |
CN111617258A (zh) * | 2019-02-28 | 2020-09-04 | 江苏恒瑞医药股份有限公司 | 一种制备阿比特龙或其衍生物药物组合物的方法及其应用 |
CZ2019168A3 (cs) | 2019-03-20 | 2020-09-30 | Zentiva, K.S. | Farmaceutická kompozice obsahující abirateron acetát |
CN110170058B (zh) * | 2019-06-24 | 2022-02-11 | 李建恒 | 一种阿比特龙包合物及其制备方法 |
CN116785301A (zh) | 2019-09-26 | 2023-09-22 | 湖南慧泽生物医药科技有限公司 | 含醋酸阿比特龙的药物组合物及其制备方法和应用 |
CN117881411A (zh) * | 2021-06-01 | 2024-04-12 | 艾迪雅生物有限责任公司 | 用于眼部药物的延长释放药物递送系统和使用方法 |
EP4197541A1 (en) | 2021-12-15 | 2023-06-21 | Hunan Huize Biopharma S&T Co., Ltd | Abiraterone acetate-containing composition and application thereof |
WO2024080308A1 (ja) * | 2022-10-12 | 2024-04-18 | 中外製薬株式会社 | ペプチド、界面活性剤及びポリマーを含む組成物 |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5604213A (en) | 1992-03-31 | 1997-02-18 | British Technology Group Limited | 17-substituted steroids useful in cancer treatment |
DE69417248T2 (de) | 1993-10-27 | 1999-08-19 | Merrell Pharma Inc | Delta 16 ungesättigtes c17 heterocyclische steroide zur verwendung als steroid c17-20 lyase inhibitoren |
US5688977A (en) | 1996-02-29 | 1997-11-18 | Napro Biotherapeutics, Inc. | Method for docetaxel synthesis |
ATE550022T1 (de) | 2003-02-28 | 2012-04-15 | Mcneil Ppc Inc | Pharmazeutische mischkristalle von celecoxib- nicotinamid |
WO2007150030A2 (en) * | 2006-06-23 | 2007-12-27 | Massachusetts Institute Of Technology | Microfluidic synthesis of organic nanoparticles |
US20080051380A1 (en) | 2006-08-25 | 2008-02-28 | Auerbach Alan H | Methods and compositions for treating cancer |
US20090124587A1 (en) | 2007-07-12 | 2009-05-14 | Auerbach Alan H | METHODS FOR TREATING CANCER USING 17alpha-HYDROXYLASE/C17,20-LYASE INHIBITORS |
US9278134B2 (en) | 2008-12-29 | 2016-03-08 | The Board Of Trustees Of The University Of Alabama | Dual functioning ionic liquids and salts thereof |
CN101768199B (zh) | 2009-12-24 | 2014-03-26 | 深圳万乐药业有限公司 | 醋酸阿比特龙的多晶型物及其制备方法 |
HUP1000325A2 (en) * | 2010-06-18 | 2012-01-30 | Druggability Technologies Ip Holdco Jersey Ltd | Nanostructured aprepitant compositions and process for their preparation |
CN102558275A (zh) | 2010-12-20 | 2012-07-11 | 天津药物研究院 | α型多晶型醋酸阿比特龙结晶、其制备方法、用途和药物组合物 |
ES2823805T3 (es) * | 2011-04-15 | 2021-05-10 | Janssen Pharmaceutica Nv | Nanosuspensiones de fármacos secadas por congelamiento |
CN102321142A (zh) | 2011-09-29 | 2012-01-18 | 重庆医药工业研究院有限责任公司 | 一种醋酸阿比特龙晶型及其制备方法 |
CN102336801B (zh) | 2011-10-31 | 2013-05-15 | 南京卡文迪许生物工程技术有限公司 | 醋酸阿比特龙多晶型物和药用组合物 |
US9662807B2 (en) * | 2011-12-21 | 2017-05-30 | GKN Aerospace Services Structures, Corp. | Method for forming a fabric preform for a composite material by separately tensioning tows |
GB201207886D0 (en) * | 2012-05-04 | 2012-06-20 | Jagotec Ag | Improvements in or relating to organic compounds |
WO2014009434A1 (en) | 2012-07-11 | 2014-01-16 | Sandoz Ag | Self-microemulsifying drug delivery system of abiraterone or abiraterone acetate |
WO2014009436A1 (en) * | 2012-07-11 | 2014-01-16 | Sandoz Ag | Nanosuspension of abiraterone acetate |
WO2014009437A1 (en) * | 2012-07-11 | 2014-01-16 | Sandoz Ag | Oxidation stability of abiraterone acetate |
WO2014083512A1 (en) | 2012-11-28 | 2014-06-05 | Dr. Reddy's Laboratories Limited | Process for preparation of abiraterone acetate |
RU2015128794A (ru) | 2012-12-20 | 2017-01-25 | КАШИВ ФАРМА, ЭлЭлСи | Композиция перорально распадающейся таблетки, обеспечивающая повышенную биодоступность |
WO2014102833A2 (en) | 2012-12-31 | 2014-07-03 | Hetero Research Foundation | Process for abiraterone acetate |
CA2907415C (en) | 2013-03-15 | 2022-04-05 | Iceutica Inc. | Abiraterone acetate formulation |
EP2813212A1 (en) * | 2013-06-10 | 2014-12-17 | Zentiva, a.s. | Drug formulation using API in nanofibers |
HUP1500055A1 (hu) | 2015-02-09 | 2016-08-29 | Druggability Technologies Ip Holdco Ltd | Abirateron acetát komplexei, eljárás elõállításukra, és az azokat tartalmazó gyógyászati készítmények |
-
2015
- 2015-02-09 HU HU1500055A patent/HUP1500055A1/hu unknown
-
2016
- 2016-02-04 TW TW105103892A patent/TWI696463B/zh not_active IP Right Cessation
- 2016-02-09 RU RU2017129740A patent/RU2017129740A/ru not_active Application Discontinuation
- 2016-02-09 EP EP16705303.2A patent/EP3256108B1/en active Active
- 2016-02-09 WO PCT/IB2016/050672 patent/WO2016128891A1/en active Application Filing
- 2016-02-09 CN CN201680009531.4A patent/CN107278152A/zh active Pending
- 2016-02-09 JP JP2017541778A patent/JP6697473B2/ja active Active
- 2016-02-09 SG SG11201706273QA patent/SG11201706273QA/en unknown
- 2016-02-09 BR BR112017017089-2A patent/BR112017017089A2/pt not_active Application Discontinuation
- 2016-02-09 CA CA2976053A patent/CA2976053A1/en not_active Abandoned
- 2016-02-09 MX MX2017010280A patent/MX2017010280A/es active IP Right Grant
- 2016-02-09 HU HUE16705303A patent/HUE045398T2/hu unknown
- 2016-02-09 US US15/019,037 patent/US9623034B2/en active Active
- 2016-02-09 PL PL16705303T patent/PL3256108T3/pl unknown
- 2016-02-09 ES ES16705303T patent/ES2737955T3/es active Active
- 2016-02-09 AU AU2016217534A patent/AU2016217534A1/en not_active Abandoned
- 2016-02-10 AR ARP160100363A patent/AR103653A1/es unknown
- 2016-07-28 US US15/222,301 patent/US9592244B2/en active Active
-
2017
- 2017-03-13 US US15/456,988 patent/US10130582B2/en active Active
- 2017-08-02 IL IL253793A patent/IL253793B/en active IP Right Grant
-
2018
- 2018-05-04 HK HK18105756.3A patent/HK1246189B/zh unknown
- 2018-10-17 US US16/163,130 patent/US10668016B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
IL253793A0 (en) | 2017-09-28 |
CA2976053A1 (en) | 2016-08-18 |
TWI696463B (zh) | 2020-06-21 |
SG11201706273QA (en) | 2017-08-30 |
CN107278152A (zh) | 2017-10-20 |
MX2017010280A (es) | 2017-12-04 |
JP6697473B2 (ja) | 2020-05-20 |
RU2017129740A3 (pt) | 2019-08-06 |
AR103653A1 (es) | 2017-05-24 |
HK1246189B (zh) | 2020-03-27 |
ES2737955T3 (es) | 2020-01-17 |
US20160331763A1 (en) | 2016-11-17 |
EP3256108B1 (en) | 2019-05-01 |
EP3256108A1 (en) | 2017-12-20 |
US10668016B2 (en) | 2020-06-02 |
PL3256108T3 (pl) | 2019-12-31 |
JP2018504443A (ja) | 2018-02-15 |
HUP1500055A1 (hu) | 2016-08-29 |
US20170182172A1 (en) | 2017-06-29 |
AU2016217534A1 (en) | 2017-09-07 |
WO2016128891A1 (en) | 2016-08-18 |
RU2017129740A (ru) | 2019-03-11 |
US9592244B2 (en) | 2017-03-14 |
US10130582B2 (en) | 2018-11-20 |
US20190046437A1 (en) | 2019-02-14 |
IL253793B (en) | 2021-02-28 |
US20160228455A1 (en) | 2016-08-11 |
US9623034B2 (en) | 2017-04-18 |
HUE045398T2 (hu) | 2019-12-30 |
TW201639580A (zh) | 2016-11-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112017017089A2 (pt) | complexos de acetato de abiraterona, processo para preparação destes e composições farmacêuticas contendo-os | |
IL282304A (en) | Pharmaceutical preparations for local use | |
IL254714A0 (en) | History of quinoline and pharmaceutical preparations containing them | |
ZA201601656B (en) | Inhalable pharmaceutical composition | |
HK1231390A1 (zh) | 用於局部給藥的藥用組合物 | |
IL258977B (en) | Pyperidyl derivatives, their preparation and pharmaceutical compositions containing them | |
HUE047860T2 (hu) | Ellenanyagot tartalmazó gyógyászati készítmény | |
GB201502845D0 (en) | Topical pharmaceutical formulation | |
HK1222336A1 (zh) | 包含膽鹼及其衍生物的組合物、其用途以及其製備方法 | |
EP3284743A4 (en) | Heterocyclic-imidazole compounds, pharmaceutical compositions thereof, preparation method therefor and use thereof | |
PL3313370T3 (pl) | Okulistyczna kompozycja farmaceutyczna | |
PL3250188T3 (pl) | Kompozycja farmaceutyczna zawierająca Aprepitant oraz sposób jej wytwarzania | |
IL262929B1 (en) | Preparations for treatment, methods of their preparation and their uses | |
MA42111A (fr) | Compositions pharmaceutiques topiques | |
SG10201912650QA (en) | Nanoliposomes comprising corticosteroid as medicaments and methods to prepare them | |
SG11201708197QA (en) | Pharmaceutical composition for skin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B07G | Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette] |
Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021 |
|
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |